Multicenter study confirms low testosterone in 84 percent of lung cancer patients taking crizotinib

April 16, 2013, University of Colorado Denver

A previous study by the University of Colorado Cancer Center reported the common side effect of low testosterone in men treated with the recently approved lung cancer agent, crizotinib. A new study published this week in the journal Cancer confirms this finding in a multi-national sample, details the mechanism of reduced testosterone, and provides promising preliminary evidence that widely available hormone replacement therapies can alleviate this side effect in many patients.

"This was a wonderful collaboration between multiple centers confirming a side effect that had not been noted when the drug was initially approved by the FDA," says Ross Camidge, MD, PhD, investigator at the CU Cancer Center, director of the thoracic oncology clinical program at University of Colorado Hospital, and the paper's senior author.

Specifically, the study – which included researchers in the United States, Hong Kong, Italy and the UK – found that in 84 percent of men treated with crizotinib, were below the lower limit of normal. Importantly, this study also showed, for the first time, that approximately 80 percent of these men had symptoms associated with their low such as or depression.

Testosterone levels seemed to fall for two main reasons. First, the proteins and SHBG that bind testosterone in the blood and act as a storage depot for the hormone dropped rapidly with crizotinib use. Additionally, free testosterone – the functional form of the hormone that is liberated from these proteins – was also reduced, implying that in addition to challenging the body's ability to store testosterone, crizotinib also challenges the body's ability to produce it. Camidge and colleagues went on to show that when low levels are found, testosterone replacement therapy may alleviate these symptoms.

"With advances in targeted therapies and in the we can use to select who to best give these new treatments to, we're starting to see drugs being approved more quickly and based on the results from far smaller numbers of patients than ever before. That's great: it helps streamline the path of these drugs into clinics where they can benefit patients who desperately need them. However, it also puts the onus on clinicians who then start using these drugs in day-to-day practice to recognize either subtle or later onset side effects that may have been missed during the initial testing," Camidge says.

For example, he says, it's perhaps not surprising that the potential for lowered testosterone was overlooked during the lightning-fast approval process for crizotinib: "If you don't specifically ask a man about symptoms of low testosterone, unless you know the patient very well, he may not feel comfortable bringing these issues up himself," Camidge says.

Now with the possibility of low testosterone in mind, clinicians who prescribe crizotinib to their male patients will know to ask about these symptoms and to test their testosterone levels. "With each breakthrough we're really trying to put people with advanced cancer back in control of their own lives," says Camidge. "The more we can make these highly effective new treatments tolerable, the closer we are to achieving that goal."

Explore further: Testosterone therapy improves sexual interest, function in older men

Related Stories

Testosterone therapy improves sexual interest, function in older men

June 29, 2016
Older men with low libido and low testosterone levels showed more interest in sex and engaged in more sexual activity when they underwent testosterone therapy, according to a new study published in the Endocrine Society's ...

Low testosterone thresholds established for type 2 diabetes

August 25, 2016
Research into type 2 diabetes conducted by Western Sydney University has for the first time established a range of clinical thresholds for testosterone levels in men associated with developing diabetes.

Doctors urged to be cautious when treating low testosterone

August 30, 2016
Doctors have been advised to exercise caution when prescribing testosterone treatment for older men with low testosterone and a history of cardiovascular disease, according to a position statement published today in the Medical ...

Testosterone undecanoate cuts anemia in hypogonadal men

April 18, 2016
(HealthDay)—Testosterone undecanoate reduces anemia in patients with subnormal testosterone levels, according to a study published in the April issue of The Journal of Urology.

Testosterone undecanoate improves sexual function in men with type 2 diabetes

May 6, 2016
In a recent placebo-controlled study, long acting testosterone undecanoate (an ester of testosterone) improved erectile function, intercourse satisfaction, and sexual desire scores in type 2 diabetic men with severe hypogonadism, ...

New crizotinib side-effect: Reduced measures of kidney function during treatment (recovery after)

November 21, 2013
A University of Colorado Cancer Center study published today in the journal Cancer shows that using crizotinib to treat ALK positive non-small cell lung cancer (NSCLC) appears to reduce kidney function when assessed by one ...

Recommended for you

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

Catching up to brain cancer: Researchers develop accurate model of how aggressive cancer cells move and spread

February 15, 2018
A brief chat at a Faculty Senate meeting put two University of Delaware researchers onto an idea that could be of great value to cancer researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.